ANTIPHOSPHOLIPID SYNDROME (APS)
Clinical trials for ANTIPHOSPHOLIPID SYNDROME (APS) explained in plain language.
Never miss a new study
Get alerted when new ANTIPHOSPHOLIPID SYNDROME (APS) trials appear
Sign up with your email to follow new studies for ANTIPHOSPHOLIPID SYNDROME (APS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial aims to tame rare clotting disorder
Disease control Recruiting nowThis study tests the safety of an experimental drug called anifrolumab in 20 adults with antiphospholipid syndrome (APS), a condition that raises the risk of blood clots and pregnancy complications. Participants receive weekly injections of the drug for up to 52 weeks, alongside …
Matched conditions: ANTIPHOSPHOLIPID SYNDROME (APS)
Phase: PHASE2 • Sponsor: National and Kapodistrian University of Athens • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug targets immune overdrive in six rare diseases
Disease control Recruiting nowThis early-stage trial is testing a drug called RAY121 in 144 people with one of six immune diseases, including antiphospholipid syndrome and bullous pemphigoid. The drug works by blocking a specific part of the immune system (the complement pathway) that can cause tissue damage.…
Matched conditions: ANTIPHOSPHOLIPID SYNDROME (APS)
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Experimental cell therapy takes on lupus and other autoimmune diseases
Disease control Recruiting nowThis early-stage trial is testing a new treatment called YTS109 for people with severe autoimmune diseases like lupus and Sjogren's syndrome that have come back or not responded to standard care. About 18 adults will receive a single infusion of these specially engineered immune …
Matched conditions: ANTIPHOSPHOLIPID SYNDROME (APS)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New cell therapy hopes to tame tough autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell treatment called YTS109 in 18 adults with hard-to-treat autoimmune diseases like lupus and scleroderma. Participants receive a single infusion of these specially designed cells. The main goal is to check if the treatment is safe, and also t…
Matched conditions: ANTIPHOSPHOLIPID SYNDROME (APS)
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New study tests safer blood thinners for Clot-Prone patients
Knowledge-focused Recruiting nowThis study looks at two types of blood thinners—direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs)—to see which works better at preventing repeat blood clots in people with a low-risk form of antiphospholipid syndrome (APS). APS is an autoimmune condition that ra…
Matched conditions: ANTIPHOSPHOLIPID SYNDROME (APS)
Sponsor: Infanta Leonor University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
200 APS patients tracked to uncover Real-World clot recurrence rates
Knowledge-focused Recruiting nowThis study follows 200 adults with antiphospholipid syndrome (APS) to see how often blood clots return and how well current treatments work. Researchers will also look at treatment side effects, risk factors, and death rates. No new treatment is being tested; the goal is to gathe…
Matched conditions: ANTIPHOSPHOLIPID SYNDROME (APS)
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:49 UTC